Gilteritinib in FLT3 mutated AML patients

Mark Levis, MD, PhD, talks about new information about gilteritinib in FLT3 mutated acute myeloid leukemia (AML) at ASCO 2018. Author: obr Added: 07/20/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts